Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Cardiology

Restoring Blood Flow: Stents, Clot Busters, and Surgery

At a Glance

Coronary thrombosis causing a heart attack requires urgent treatment to restore blood flow and limit heart damage. Angioplasty with a stent is preferred when available quickly; selected patients may receive clot-busting medicine or bypass surgery based on timing, anatomy, and bleeding risk.

When a heart attack strikes, the medical team operates under one golden rule: time is muscle. This means that every minute an artery remains blocked, heart muscle cells are being injured or lost. The goal of hospital treatment is reperfusion—the swift restoration of blood flow to the heart muscle to minimize permanent damage [1][2].

The Gold Standard: Primary PCI

For most patients having a major heart attack (STEMI), the preferred treatment is Primary Percutaneous Coronary Intervention (PCI), often called angioplasty [3][4].

During this procedure, a thin tube (catheter) is threaded through an artery in your wrist or groin up to your heart. Once the blockage is found, the doctor uses a small balloon to push the plaque aside and a stent—a tiny wire mesh tube—to prop the artery open [5].

  • Door-to-Balloon Time: Hospitals aim for a “door-to-balloon” time of 90 minutes or less for patients who arrive directly at a PCI-capable hospital [6].
  • Intraprocedural Medications: To keep your blood from clotting during the procedure, you are given potent procedural anticoagulants like unfractionated heparin or bivalirudin [7][5]. These are usually given only during the procedure and are not the same as the daily antiplatelet pills you will take at home.

Fibrinolytics: The “Clot Busters”

If you are at a hospital that does not have a cardiac catheterization lab, and it would take too long (more than 120 minutes) to transport you to one, doctors may use fibrinolytic therapy for selected STEMI patients [3][8].

These are powerful medications—often called “clot busters”—given through an IV to dissolve the clot blocking the artery. The goal is to start this medication within 30 minutes of your arrival (“door-to-needle” time). Because these drugs carry a risk of major bleeding (including intracranial hemorrhage), your doctor will carefully check for contraindications [9]. Usually, after receiving a clot buster, you will still undergo a planned angiogram within a recommended interval to ensure the artery has opened properly; if the clot buster fails, you will need urgent “rescue PCI” [10][8].

When Surgery is Necessary: CABG

While most blockages can be fixed with a stent, some situations require Coronary Artery Bypass Grafting (CABG), commonly known as bypass surgery. In CABG, a surgeon uses a healthy blood vessel from another part of your body (like your leg or chest) to create a “detour” around the blocked artery [11].

Your medical team may evaluate you for CABG if:

  • Complex Anatomy: You have blockages in many different arteries (multivessel disease) or the main “trunk” of your left coronary artery is blocked [11][12].
  • Diabetes: Research shows that patients with diabetes and complex multivessel disease often have better long-term outcomes with surgery than with stents, though it depends on many individual factors like surgical risk and ventricular function [13][14].
  • Unsuccessful PCI: If a doctor cannot safely open your artery using a stent, emergency surgery may be the next step [11].

The Heart Team Approach

For complex cases where the choice between a stent and surgery isn’t clear, hospitals often use a Heart Team approach. This involves a group of specialists—including your cardiologist and a heart surgeon—who review your imaging (such as your SYNTAX score, which measures the complexity of your blockages) and clinical history to recommend the safest and most effective path forward for you [15][16].

Reperfusion: Why It Matters

Whether through a stent, medication, or surgery, the priority is restoring oxygen to the heart. Total “ischemic time”—the time from your first symptom until the artery is reopened—is the strongest predictor of how much heart muscle will be saved [1]. This is why emergency teams work with such intense speed and why “time is muscle” remains the central philosophy of heart attack care [2][17].

Common questions in this guide

What is the usual first treatment for a coronary thrombosis during a STEMI?
Most patients with a STEMI are treated with primary PCI, also called angioplasty, when a suitable catheterization lab can be reached quickly. A balloon opens the blockage and a stent helps keep the coronary artery open. The goal is to restore blood flow as soon as possible and limit heart-muscle injury.
When are clot-busting medicines used instead of a stent?
Fibrinolytic, or clot-busting, medicine may be used for selected STEMI patients when a PCI-capable hospital cannot be reached within about 120 minutes. It is given through an IV and can cause serious bleeding, so clinicians check for contraindications. Patients usually still need a planned angiogram, and rescue PCI if the artery does not open.
How quickly should treatment start after a heart attack?
Treatment should begin as quickly as possible because each minute of blocked blood flow can injure more heart muscle. Hospitals generally aim for a door-to-balloon time of 90 minutes or less for patients who arrive directly at a PCI-capable hospital. The total time from first symptoms to reopening the artery is also important.
Why would bypass surgery be chosen over a stent?
CABG, or bypass surgery, may be considered when several coronary arteries are blocked, the left main coronary artery is involved, or PCI cannot safely open the artery. People with diabetes and complex multivessel disease may also have better long-term outcomes with surgery in some circumstances. The decision depends on anatomy, heart function, surgical risk, and other individual factors.
What does the Heart Team do when choosing between a stent and bypass surgery?
A Heart Team brings together specialists such as a cardiologist and heart surgeon to compare stenting with bypass surgery in complex cases. They review coronary imaging, the complexity of the blockages, clinical history, and measures such as the SYNTAX score. Their recommendation is tailored to the safest and most effective option for the patient.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my 'door-to-balloon' time, and how does that compare to the standard goals?
  2. 2.If I received a 'clot buster' drug, is a follow-up angiogram planned, or have we already confirmed the artery is open?
  3. 3.Why was a stent chosen for my procedure instead of bypass surgery (CABG)?
  4. 4.Does my coronary anatomy show multivessel disease that might require a Heart Team discussion for future treatments?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Time Delay, Infarct Size, and Microvascular Obstruction After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction.

    Redfors B, Mohebi R, Giustino G, et al.

    Circulation. Cardiovascular interventions 2021; (14(2)):e009879 doi:10.1161/CIRCINTERVENTIONS.120.009879.

    PMID: 33440999
  2. 2

    Coronary intervention door-to-balloon time and outcomes in ST-elevation myocardial infarction: a meta-analysis.

    Foo CY, Bonsu KO, Nallamothu BK, et al.

    Heart (British Cardiac Society) 2018; (104(16)):1362-1369 doi:10.1136/heartjnl-2017-312517.

    PMID: 29437704
  3. 3

    Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme.

    Danchin N, Popovic B, Puymirat E, et al.

    European heart journal 2020; (41(7)):858-866 doi:10.1093/eurheartj/ehz665.

    PMID: 31539043
  4. 4

    Nationwide Analysis of Patients With ST-Segment-Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention: Findings From the American Heart Association Mission: Lifeline Program.

    Dauerman HL, Bates ER, Kontos MC, et al.

    Circulation. Cardiovascular interventions 2015; (8(5)).

    PMID: 25901044
  5. 5

    Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.

    Li Y, Liang Z, Qin L, et al.

    Lancet (London, England) 2022; (400(10366)):1847-1857 doi:10.1016/S0140-6736(22)01999-7.

    PMID: 36351459
  6. 6

    Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock.

    Kochar A, Al-Khalidi HR, Hansen SM, et al.

    JACC. Cardiovascular interventions 2018; (11(18)):1824-1833 doi:10.1016/j.jcin.2018.06.030.

    PMID: 30236355
  7. 7

    Antithrombotic therapy for patients with STEMI undergoing primary PCI.

    Franchi F, Rollini F, Angiolillo DJ

    Nature reviews. Cardiology 2017; (14(6)):361-379 doi:10.1038/nrcardio.2017.18.

    PMID: 28230176
  8. 8

    Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Practical perspectives based on data from the TREAT study.

    Berwanger O, Abdelhamid M, Alexander T, et al.

    Clinical cardiology 2018; (41(10)):1322-1327 doi:10.1002/clc.23043.

    PMID: 30098028
  9. 9

    Disparity in ST-segment Elevation Myocardial Infarction Practices and Outcomes in Arabian Gulf Countries (Gulf COAST Registry).

    Zubaid M, Rashed W, Alsheikh-Ali AA, et al.

    Heart views : the official journal of the Gulf Heart Association 2017; (18(2)):41-46 doi:10.4103/HEARTVIEWS.HEARTVIEWS_113_16.

    PMID: 28706594
  10. 10

    Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction: A Propensity Score-Matched Analysis.

    Sim DS, Jeong MH, Ahn Y, et al.

    Circulation. Cardiovascular interventions 2016; (9(9)).

    PMID: 27582112
  11. 11

    [Coronary Artery Bypass Surgery in Acute Coronary Syndrome].

    Takase S, Yokoyama H

    Kyobu geka. The Japanese journal of thoracic surgery 2015; (68(8)):603-9.

    PMID: 26197901
  12. 12

    Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.

    Holck EN, Holm NR, Hildick-Smith D, et al.

    Lancet (London, England) 2026; (407(10536)):1374-1382 doi:10.1016/S0140-6736(26)00205-9.

    PMID: 41936368
  13. 13

    Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG).

    Pandey A, McGuire DK, de Lemos JA, et al.

    Circulation. Cardiovascular quality and outcomes 2016; (9(3)):197-205 doi:10.1161/CIRCOUTCOMES.115.002084.

    PMID: 27166210
  14. 14

    Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.

    Head SJ, Milojevic M, Daemen J, et al.

    Lancet (London, England) 2018; (391(10124)):939-948 doi:10.1016/S0140-6736(18)30423-9.

    PMID: 29478841
  15. 15

    [The heart team in planning and performance of revascularization : ESC guidelines versus clinical routine].

    Sinning JM, Welz A, Nickenig G

    Herz 2016; (41(7)):562-565 doi:10.1007/s00059-016-4477-6.

    PMID: 27596003
  16. 16

    Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary Disease.

    Qintar M, Humphries KH, Park JE, et al.

    Journal of the American College of Cardiology 2019; (74(16)):2074-2084 doi:10.1016/j.jacc.2019.07.083.

    PMID: 31623766
  17. 17

    Prehospital Activation of the Cardiac Catheterization Laboratory in ST-Segment-Elevation Myocardial Infarction for Primary Percutaneous Coronary Intervention.

    Savage ML, Hay K, Vollbon W, et al.

    Journal of the American Heart Association 2023; (12(14)):e029346 doi:10.1161/JAHA.122.029346.

    PMID: 37449585

This page is for informational purposes only and does not constitute medical advice. Treatment for coronary thrombosis depends on your emergency evaluation, coronary anatomy, bleeding risk, and cardiology team's recommendations.

Get notified when new evidence is published on coronary thrombosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.